Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Royalty Pharma PLC
F:RPD
Royalty Pharma PLC
F:RPD
Price:
49.955
EUR
-1.53%
Market Closed
Market Cap:
€29.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Royalty Pharma PLC
F:RPD
|
US |
|
T
|
Takeda Pharmaceutical Co Ltd
SWB:TKDA
|
JP |
|
A
|
Archrock Inc
F:54E
|
US |
Wall St Price Targets
RPD Price Forecast
Based on 12 analysts
Based on 12 analysts
-29% Downside
from
€49.955
today
Royalty Pharma PLC (RPD)’s 12-month stock price forecast through September 2027 has a consensus target of €35.28, implying 29% downside. The forecast is based on price targets from 12 Wall Street analysts.
RPD Analyst Rating
No ratings yet
No ratings yet
Royalty Pharma PLC Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPD's stock price target?
Price Target
35.28
EUR
35.28
EUR
According to Wall Street analysts, the average 1-year price target for RPD is 35.28 EUR with a low forecast of 24.534 EUR and a high forecast of 38.813 EUR.
What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
18%
18%
Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 18%.
What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
31%
31%
Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 3 years is 31%.
What is the Pre-Tax Income forecast for Royalty Pharma PLC?
Projected CAGR
38%
38%
Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -2%. The projected CAGR for the next 3 years is 38%.
What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
64%
64%
Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 3 years is 64%.